ストックスクリーナーアプリを入手
2.12
1.85%
-0.04
アフターアワーズ：
2.12
前日終値:
$2.16
開ける：
$2.13
24時間の取引高:
814.46K
Relative Volume:
1.14
時価総額：
$235.37M
収益：
$21.05M
当期純損益:
$-142.93M
株価収益率:
-1.5257
EPS:
-1.3895
ネットキャッシュフロー:
$-184.07M
1週間 パフォーマンス:
+3.41%
1か月 パフォーマンス:
-17.51%
6か月 パフォーマンス:
+66.93%
1年 パフォーマンス:
+73.77%
1日の値動き範囲:
$2.045
$2.18
1週間の範囲:
$2.03
$2.37
52週間の値動き範囲:
$1.09
$3.3999
Alector Inc Stock (ALEC) Company Profile
名前
Alector Inc
セクター
電話
415-231-5660
住所
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Compare ALEC vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
2.12 | 239.81M | 21.05M | -142.93M | -184.07M | -1.3895 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2026-03-10 | アップグレード | BTIG Research | Neutral → Buy |
| 2025-10-22 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-10-22 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-22 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-10-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-10-22 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-07-28 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-17 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-04 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-11-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-11-26 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-14 | アップグレード | Stifel | Hold → Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-09-25 | 開始されました | Goldman | Sell |
| 2023-09-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-04-13 | 開始されました | Goldman | Sell |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-27 | 開始されました | William Blair | Outperform |
| 2021-01-15 | 再開されました | BofA Securities | Buy |
| 2020-06-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-19 | 開始されました | Stifel | Buy |
| 2019-11-21 | 開始されました | BTIG Research | Buy |
| 2019-03-04 | 開始されました | Barclays | Overweight |
| 2019-03-04 | 開始されました | BofA/Merrill | Buy |
| 2019-03-04 | 開始されました | Morgan Stanley | Overweight |
| 2019-03-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Alector Inc (ALEC) 最新ニュース
Polaris entities hold 4.85M ALEC shares (ALEC) — Amendment No.7 - Stock Titan
Alector (ALEC)'s technical outlook is bright after key golden cross - MSN
TradingKey - TradingKey
Alector Establishes $125 Million At-the-Market Offering - The Globe and Mail
Myles Minter Reiterates Hold on Alector as Late-Stage Trial Failures Trigger Pipeline Reset but Next-Gen Brain Carrier Platform Offers Long-Term Optionality - TipRanks
Alector (ALEC) Reports Q1 Revenue Shortfall Amidst Strategic Dev - GuruFocus
Alector, Inc. Announces $125 Million Common Stock Sales Agreement with TD Securities (USA) LLC - Minichart
Alector: Q1 Earnings Snapshot - theheraldreview.com
Alector posts first quarter 2026 financial results amid new business updates - Traders Union
Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Alector (NASDAQ: ALEC) establishes $125M stock ATM facility - Stock Titan
Alector (NASDAQ: ALEC) files $125M ATM offering with TD Cowen - Stock Titan
Alector (NASDAQ: ALEC) narrows Q1 2026 loss as it refocuses pipeline - Stock Titan
Alector Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Alector | 10-Q: Q1 2026 Earnings Report - Moomoo
Alector | 8-K: Alector Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus - Stock Titan
BRIEF-Alector Q1 Basic EPS USD -0.21 - TradingView
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
MSN Money - MSN
Transcript : Alector, Inc.Special Call - marketscreener.com
Alector Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Five-Way Obesity Drug Shows Effectiveness in Mice; Alector Stops Alzheimer’s Trial - geneonline.com
Franklin Lexington Private Markets Fund's Alector Inc(ALEC) Holding History - GuruFocus
Morgan Stanley raises Alector stock price target on pipeline focus By Investing.com - Investing.com Australia
Morgan Stanley raises Alector stock price target on pipeline focus - Investing.com
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Alector (ALEC) - The Globe and Mail
Failure of GSK-partnered Alzheimer’s drug a fresh setback for Alector - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC) and Alector (ALEC) - The Globe and Mail
Peninsula biotech Alector loses another Alzheimer's battle, shifts to earlier-stage programs - The Business Journals
Alector drops GSK-partnered Alzheimer’s drug (ALEC:NASDAQ) - Seeking Alpha
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk - Yahoo Finance
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints - BioSpace
5AM Venture Management, LLC's Alector Inc(ALEC) Holding History - GuruFocus
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis - The Manila Times
Biopharmaceutical company Alector Inc. announced that it will discontinue its Phase II PROGRESS-AD clinical trial of its candidate drug Nivisnebart (development code AL101/GSK4527226) for the treatment of early-stage Alzheimer's disease. - Bitget
Alector to discontinue phase 2 trial of nivisnebart - marketscreener.com
Alector to Discontinue Phase 2 PROGRESS-AD Trial of - GlobeNewswire
Alzheimer’s drug study stops early after review finds low odds of success - Stock Titan
Cantor Fitzgerald upgrades Alector (ALEC) - MSN
Alector (NASDAQ: ALEC) sets 2026 virtual meeting on directors, auditor and say-on-pay - Stock Titan
Alector | ARS: Annual Report to Security Holders - Moomoo
BlackRock (ALEC) discloses 5.2% ownership of Alector common stock - Stock Titan
Alector gains as Cantor Fitzgerald upgrades on brain carrier platform - MSN
Alector | SCHEDULE 13G: Others - Moomoo
Alector (ALEC) Price Target Decreased by 42.61% to 2.24 - MSN
Alector Inc (ALEC) 財務データ
収益
当期純利益
現金流量
EPS
2.53%
大文字化:
|
ボリューム (24 時間):